Login / Signup

C-terminal glutamine acts as a C-degron targeted by E3 ubiquitin ligase TRIM7.

Yawei RuXiaojie YanBing ZhangLili SongQiqi FengChen YeZhili ZhouZhenzhen YangYao LiZhenjian ZhangQianqian LiWenyi MiCheng Dong
Published in: Proceedings of the National Academy of Sciences of the United States of America (2022)
The exposed N-terminal or C-terminal residues of proteins can act, in cognate sequence contexts, as degradation signals (degrons) that are targeted by specific E3 ubiquitin ligases for proteasome-dependent degradation by N -degron or C-degron pathways. Here, we discovered a distinct C-degron pathway, termed the Gln/C-degron pathway, in which the B30.2 domain of E3 ubiquitin ligase TRIM7 (TRIM7 B30.2 ) mediates the recognition of proteins bearing a C-terminal glutamine. By determining crystal structures of TRIM7 B30.2 in complexes with various peptides, we show that TRIM7 B30.2 forms a positively charged binding pocket to engage the "U"-shaped Gln/C-degron. The four C-terminal residues of a substrate play an important role in C-degron recognition, with C-terminal glutamine as the principal determinant. In vitro biochemical and cellular experiments were used to further analyze the substrate specificity and selective degradation of the Gln/C-degron by TRIM7.
Keyphrases
  • cancer therapy
  • drug delivery
  • oxidative stress